0.195
0.01 (2.63%)
Previous Close | 0.190 |
Open | 0.190 |
Volume | 91,249 |
Avg. Volume (3M) | 469,374 |
Market Cap | 44,666,892 |
Price / Sales | 1.36 |
Price / Book | 1.66 |
52 Weeks Range | |
Earnings Date | 26 Aug 2024 |
Profit Margin | -37.69% |
Operating Margin (TTM) | -25.50% |
Diluted EPS (TTM) | -0.040 |
Quarterly Revenue Growth (YOY) | 52.70% |
Total Debt/Equity (MRQ) | 15.70% |
Current Ratio (MRQ) | 2.60 |
Operating Cash Flow (TTM) | -7.86 M |
Levered Free Cash Flow (TTM) | -4.92 M |
Return on Assets (TTM) | -18.61% |
Return on Equity (TTM) | -39.49% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (AU) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | NOVA EYE FPO [EYE] | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 0.63 |
Nova Eye Medical Ltd is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of its revenue from the United States of America. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Value |
% Held by Insiders | 18.59% |
% Held by Institutions | 18.75% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |